Charles River Laboratories International, Inc.
CRL · NYSE
12/31/2024 | 12/28/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | – | $25,291 | $480,370 | $492,608 |
| Dep. & Amort. | – | $361,741 | $314,124 | $303,870 |
| Deferred Tax | – | -$67,428 | -$50,903 | -$35,884 |
| Stock-Based Comp. | – | $69,891 | $72,048 | $73,617 |
| Change in WC | – | -$30,329 | -$102,380 | -$152,554 |
| Other Non-Cash | – | $375,411 | -$29,361 | -$62,017 |
| Operating Cash Flow | – | $734,577 | $683,898 | $619,640 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | – | -$232,967 | -$318,528 | -$324,733 |
| Net Acquisitions | – | -$5,479 | -$194,785 | -$120,117 |
| Inv. Purchases | – | -$52,876 | -$54,215 | -$158,274 |
| Inv. Sales/Matur. | – | $41,687 | $6,667 | $4,549 |
| Other Inv. Act. | – | $4,549 | -$2,294 | -$9,347 |
| Investing Cash Flow | – | -$245,086 | -$563,155 | -$607,922 |
| Financing Activities | – | – | – | – |
| Debt Repay. | – | -$412,188 | -$75,323 | $19,794 |
| Stock Issued | – | $0 | $0 | $0 |
| Stock Repurch. | – | -$119,175 | -$24,155 | -$38,651 |
| Dividends Paid | – | $0 | $0 | $0 |
| Other Fin. Act. | – | -$19,564 | $13,957 | -$23,540 |
| Financing Cash Flow | – | -$550,927 | -$85,521 | -$42,397 |
| Forex Effect | – | -$17,474 | $8,044 | $25,579 |
| Net Chg. in Cash | – | -$78,910 | $43,266 | -$5,100 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | – | $284,480 | $241,214 | $246,314 |
| End Cash | – | $205,570 | $284,480 | $241,214 |
| Free Cash Flow | – | $501,610 | $365,370 | $294,907 |